Identification of Programmed Death Ligand 1–derived Peptides Capable of Inducing Cancer-reactive Cytotoxic T Lymphocytes From HLA-A24+ Patients With Renal Cell Carcinoma. Issue 7 (September 2015) - Minami, Takafumi
Abstract : Molecular therapy targeting tumor angiogenesis has been the standard treatment for metastatic renal cell carcinoma (mRCC). However, despite their significant antitumor effects, most of patients with mRCC have not been cured. Under such circumstances, anticancer immunotherapy has been considered a promising treatment modality for mRCC, and cancer-reactive cytotoxic T lymphocytes (CTLs) are the most powerful effectors among several immune cells. However, anticancer CTLs can be inhibited by several immune inhibitory mechanisms, including the interaction between programmed death 1 (PD-1) and its ligand PD-L1, on T cells and cancer cells, respectively. Alternatively, this also means that PD-L1 could be a promising target for anticancer immunotherapy. Therefore, we searched for PD-L1-derived peptides that are applicable for anticancer vaccine for HLA-A24 + RCC patients. Among 5 peptides derived from PD-L1, which were prepared based on the binding motif to the HLA-A24 allele, both PD-L111-19 and PD-L141-50 peptides induced peptide-specific CTLs from peripheral blood mononuclear cells of HLA-A24 + RCC patients. Such PD-L1 peptide-stimulated CD8 + T cells showed cytotoxicity against HLA-A24 + and PD-L1-expressing RCC cells. Although IFN-γ treatment increased PD-L1 expression on PD-L1 low RCC cells, their sensitivity to cytotoxicity of PD-L1 peptide-stimulated CD8 + T cells varied between patients. Altogether, these results indicate that both PD-L111-19 and PD-L141-50 peptides could be candidates for peptide-based anticancer vaccines for HLA-A24 + mRCC patients.